EyeArt AI Screening Tool

Description

EyeArt by Eyenuk is a pioneering autonomous AI system designed to screen for diabetic retinopathy. It is the first and only FDA 510(k)-cleared AI technology for the autonomous detection of both more than mild and vision-threatening diabetic retinopathy (vtDR). EyeArt operates with a sensitivity of 96-97% and specificity of 88-90%, ensuring accurate and reliable results. The system is designed for use in primary care, endocrinology, optometry, and ophthalmology settings, providing a non-invasive retinal exam without the need for specialist oversight or patient dilation.

EyeArt's AI technology enables rapid screening, delivering diagnostic results in under 10 seconds. This allows healthcare providers to make immediate clinical decisions and prioritize high-risk patients for specialist referrals. The system is compatible with multiple camera models from leading manufacturers, offering flexibility and ease of integration into existing clinical workflows.

Eyenuk's EyeArt is also compliant with GDPR, HIPAA, and SOC 2 Type 2 standards, ensuring the highest levels of data security and privacy. The platform supports seamless EHR integration, minimizing administrative burdens and enhancing operational efficiency. EyeArt's capabilities extend beyond diabetic retinopathy, with the potential to detect age-related macular degeneration (AMD) and glaucomatous optic nerve damage.

The EyeArt system is globally recognized, with clearances from the EU MDR, Health Canada, and other regulatory bodies. It is designed to improve healthcare access and outcomes, particularly in underserved communities, by providing timely and accurate eye health assessments. EyeArt's autonomous AI technology represents a significant advancement in the early detection and management of diabetic retinopathy, helping to prevent vision loss and improve patient care.

EyeArt AI Screening Tool's Core Features

• FDA 510(k)-cleared for diabetic retinopathy

• 96-97% sensitivity for vtDR detection

• Non-invasive retinal exams

• No specialist required

• Compatible with multiple camera models

• GDPR, HIPAA, SOC 2 Type 2 compliant

• Seamless EHR integration

• Global regulatory clearances

How to use EyeArt AI Screening Tool?

1. 1

   Capture: Take retinal images using compatible cameras

2. 2

   Upload: Transfer images to the EyeArt system

3. 3

   Analyze: AI processes images in under 10 seconds

4. 4

   Report: Receive diagnostic results instantly

EyeArt AI Screening Tool's Use Cases

• Primary Care Screening
• Specialist Referral
• EHR Integration
• Non-Invasive Exams
• Global Health Access

FAQ from EyeArt AI Screening Tool

• What is EyeArt AI screening?

  EyeArt is an FDA-cleared autonomous AI system for diabetic retinopathy screening, providing rapid and accurate results.

• Who is eligible for EyeArt screening?

  Adults with diabetes who have not been diagnosed with more than mild diabetic retinopathy are eligible.

• Does EyeArt require pupil dilation?

  No, EyeArt is a non-mydriatic solution, allowing most patients to be screened without dilation.

• How does EyeArt integrate with EHR systems?

  EyeArt supports seamless EHR integration, minimizing manual data entry and ensuring results are documented in patient records.

• What are the security standards for EyeArt?

  EyeArt complies with GDPR, HIPAA, and SOC 2 Type 2 standards, ensuring high data security and privacy.

• How quickly does EyeArt provide results?

  EyeArt delivers diagnostic results in under 10 seconds, enabling immediate clinical decision-making.

• What camera models are compatible with EyeArt?

  EyeArt is compatible with multiple camera models, including Canon CR-2 AF and Topcon NW400.

• What regulatory clearances does EyeArt have?

  EyeArt has FDA 510(k) clearance, EU MDR Class IIb certification, and Health Canada Class II license.